Asthma Market to Witness the Highest Growth Globally in Coming Years

Asthma is a respiratory condition, where the airways become inflamed and narrow, which can cause a serious and incurable condition if left untreated. Breathlessness, wheezing and coughing are some of the symptoms of asthma and it can be controlled by avoiding triggers and with the help of drug therapy. Environmental triggers may vary from consumer to consumer but it can include exercise, smoke, cold air and other allergens such as pollen, dust mites, and infections. The wheezing in asthma begins when the chemicals present in the lungs overreact to the dust mites, cold air and exercise.

According to Centers for Disease Control and Prevention (CDC), asthma is an ordinary chronic airway disorder which is characterized by swelling of air passages that convey air from mouth and nose to lungs. Asthma is caused generally due to allergies leading to inflammation of lungs. GlaxoSmithKline Pharmaceuticals Limited and Novartis AG are developing once-a-day combination products that are longer acting than currently available drugs and more suitable for patients due to its advantage of being taken only once a day.

Request to Get the Sample Pages at: 

Based on drug class, the global asthma market can be categorized bronchodilators, combination therapies, mast cell stabilizers, leukotriene antagonists and immunosuppressants. On the basis of route of administration, the global market is segmented into oral, inhaled and other route of administrations.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=asthma-market

Daily exposure to hazardous working environment, influx of pollutants in the air, increase in population susceptible to indoor air pollutants, increase in disposable income, increasing population of smokers, improved healthcare facility, and growing aging population are some of other the major factors that are driving the growth of asthma market. Factors that are restraining the growth of asthma market are high cost of asthma treatment, patent expiry of many best-seller brands and long treatment continuation. Additionally, lack of diagnostic tools for reliable asthma diagnosis in young children is also limiting the growth of global asthma market.

Some of the major competitors of global asthma market are, Ono Pharmaceutical Co., Ltd., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd. Merck & Co., Inc., Astrazeneca plc, Sunovion Pharmaceuticals, Inc., Novartis AG, Boehringer Ingelheim GmbH, Koninklijke Philips N.V., and F. Hoffmann La-Roche Ltd.

About P&S Intelligence

P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:

P&S Intelligence

Toll-free: +1-888-778-7886 (USA/Canada)           

International: +1-347-960-6455

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Read More

Immunotherapy Drugs Market Analysis by Stages, Drug Class, Company Profile, Phase of Development, Clinical Trial, Preclinical Research & Discovery Stage Insights

The global immunotherapy drugs market valued $106.1 billion revenue in 2017 and is projected to register a CAGR of 13.6% during the period 2018–2023. Surge in the prevalence of chronic diseases, and thriving demand and development of monoclonal antibodies (mAbs) are the key factors driving the market growth.

Checkpoint inhibitors and vaccines are the two major types of immunotherapy drugs analyzed in the report. Of these, checkpoint inhibitors held a larger share in the immunotherapy drugs market, accounting for 66.3% in 2017. Checkpoint inhibitors are the first preference for the treatment of chronic diseases, as they provide better and effective treatment results. These drugs act directly on site of action, without delaying the effect of medicine, and are thus being highly adopted for the treatment of several diseases. Some of the major checkpoint inhibitors brand available in the market are Humira, Rituxan/MabThera, Herceptin, Remicade, and Enbrel.

Hospitals and clinics were the key end users in the immunotherapy drugs market, with 81.0% contribution in 2017. The adoption of immunotherapy drugs has been increasing in hospitals and clinics, owing to growing patient population, increasing healthcare expenditure, and rising prevalence of chronic diseases, leading to dominate the end-user segment.

North America was the largest immunotherapy drugs market during the historical period, with more than 50.0% contribution in 2017. This can be attributed to the increasing per capita healthcare spending, surging geriatric population, rising prevalence of chronic diseases, and growing presence of market players in the region. Furthermore, factors such as growing research collaborations, increasing number of research laboratories, and growing direct and indirect investments in research and development (R&D) by pharmaceutical and biotechnology companies will also support the growth of the regional market in the coming years.

Download Report Sample Copy at:

Globally, the rising prevalence of chronic diseases is a major healthcare burden that effects high income nations as well as low and middle-income countries (LMIC). The impact of these diseases can be ascertained from the fact that cancer is estimated to lead to 9.6 million deaths in 2018, as reported by the World Health Organisation (WHO). The organisation further stated that around 70% of deaths from cancer occur in LMIC.

Several drugs manufactured by market players for the treatment of chronic diseases are under clinical trials. Thus, increasing use of immunotherapy drugs to combat the rising prevalence of chronic diseases is an important factor driving the market demand. Moreover, thriving demand and development of mAbs, rise in the implementation of target therapy, and increasing availability of biosimilars are also contributing to the growth of the immunotherapy drugs market.

The report provides epidemiology analysis for cancer, autoimmune and inflammatory diseases, and infectious diseases. According to the International Agency for Research on Cancer (IARC) in 2018, 18.1 million people are estimated to be suffering from cancer globally, which is expected to reach 29.5 million by 2040. Another study conducted by the American Medical Association (AMA) between 2005–2015, reported that the incident of cancer cases increased by 33% during this period, of which 16.4% of the cases were due to aging population.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=immunotherapy-drugs-market

The report also covers pricing and reimbursement scenario for immunotherapy drugs on the universal level and for major countries such as the U.S., Belgium, the U.K., France, Italy, Spain, Japan, China, and Australia. For instance, a reimbursement scenario in the U.K. has impacted the cost of the drugs. Keytruda is an immunotherapy drug used for the treatment of melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell cancer (HNSCC), urothelial carcinoma, gastric cancer, and cervical cancer. Keytruda generally costs up to $84,000 to the patients. To reduce the cost of this drug, the National Health Service (NHS) England; a publicly funded national healthcare system, and Merck & Co. Inc. entered into an agreement in June 2018, to reimburse the cost of this drug and provide it for routine use as per the National Institute for Health and Care Excellence (NICE) recommendations. NICE recommends NHS to provide reimbursements for this drug and make it affordable for the patients.

Some of the other leading players operating in the global immunotherapy drugs market are F. Hoffmann-La Roche Ltd., AbbVie Inc., AstraZeneca PLC, Merck & Co. Inc., GlaxoSmithKline plc, Novartis International AG, Johnson & Johnson, Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Sanofi, Medigene AG, C. H. Boehringer Sohn AG & Co. KG, Takeda Pharmaceutical Company Limited, and Celgene Corporation.

  

MARKET SEGMENTATION
By Therapy Area

·         Cancer

o    Solid Tumor

o    Malignant

·         Autoimmune & Inflammatory Diseases

·         Infectious Diseases

·         Others

By Type of Drug

·         Monoclonal Antibodies

·         Adult Vaccines

o    Preventive Vaccines

o    Therapeutic Vaccines

·         Checkpoint Inhibitors

·         Interferons Alpha & Beta

·         Interleukins

·         Others

By End User

·         Hospitals

·         Clinics

·         Others

Geographical Segmentation

·         North America

o    U.S.

o    Canada

·         Europe

o    Germany

o    U.K

o    France

o    Italy

o    Spain

o    Rest of Europe

·         Asia-Pacific

o    China

o    India

o    Japan

o    Rest of Asia-Pacific

·         Latin America

o    Brazil

o    Mexico

o    Rest of Latin America

·         Middle East & Africa (MEA)

Read More

Needle-Free Diabetes Management Market Comprehensive Review of its Top Companies, Investment Trend, Growth Opportunities, Drivers, Technology and Future Prospects – Chemical Report

Needle-Free Diabetes Management Market Comprehensive Review of its Top Companies, Investment Trend, Growth Opportunities, Drivers, Technology and Future Prospects – Chemical Report

Read More

Breast Cancer Market Comprehensive Analysis of Market Trends, Technological Advancements, Company Profile and Growth Opportunities

Cancer is a disease characterized by uncontrolled growth of cell. There are about 100 different types of cancer and each is classified by the type of cell where it occurs and affects. Breast cancer is mostly prevalent in women, however, breast cancer in men is rare. It is frequently diagnosed in aged women and one of the leading causes of death among them. Some of the most common types of breast cancer are ductal carcinoma in situ (DCIS), lobular carcinoma and invasive ductal carcinoma.

DCIS, also known as intraductal carcinoma, begins in the lining of the milk ducts. Milk ducts are thin tubes carrying milk from lobules of the breast to the nipple. Lobule carcinoma originates in the lobules or milk glands of the breast. Invasive ductal carcinoma is the most common type of breast cancer. It starts in a milk duct of the breast, ruptures through the wall of the duct and grows into the fatty tissue of the breast. It spreads to other parts of body through bloodstream.

Request to Get the Sample Pages at:

North America accounts the largest global breast cancer market followed by Europe. The U.S., followed by Canada, is the largest market for breast cancer in North America. Key driving factor for this market is increasing prevalence of breast cancer in the region. Germany, France and the U.K. are some of the largest markets for breast cancer in Europe region. However, Asia-Pacific represents the fastest growing region in the global breast cancer market. This is due to improving healthcare infrastructure and increasing awareness among people about breast cancer. In developing countries, such as China and India, government has launched several programs and initiatives which increase awareness about the disease. It has led to significant rise in demand of breast cancer diagnostics and therapeutics for disease management. In addition, less stringent wages and availability of skilled labor attracts manufacturing companies to invest in developing countries. 

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=-breast-cancer-market

Increasing prevalence of the disease is a key driving factor for the global breast cancer market. Increasing awareness among people about the disease and rising number of geriatric women around the world are also supporting the growth of global breast cancer market. In addition, increased research in the field of oncology and development of biomarker has also fueled the growth of global breast cancer market. Increasing demand of advanced therapeutic drugs and extensive drug pipeline holds immense potential to the growth of the global breast cancer market.

Some of the major competitors in the market are Astrazeneca PLC, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Novartis AG, Sanofi-Aventis. Pfizer, Inc., Bristol-Myers Squibb Company, Bayer AG, GlaxoSmithKline plc and Teva Pharmaceutical Industries Ltd.

Read More

Bile Duct Cancer Therapeutics Market Has Been Classified on the Basis of Disease Indication, Treatment Type and Geography

Bile duct cancer is also known as cholangiocarcinoma. It involves the presence of mutated epithelial cells originated in the bile ducts. However, the cause of bile duct cancer (cholangiocarcinoma) is not certain. There are some factors that can increase the chances of developing bile duct cancer (cholangiocarcinoma).

The most common symptoms of bile duct cancer (cholangiocarcinoma) include abdominal pain, abnormal liver function, generalized itching, weight loss, discoloration of stool and urine, etc. The risk factor of bile duct cancer (cholangiocarcinoma) include liver fluke infections, cholangitis and exposure to thorium dioxide. According to American Society of Clinical Oncology (ASCO), less than 3,000 people are affected with the disease, every year, in the U.S. Also, according to Cancer Research UK, about 1,600 people are affected by the disease, every year, in the U.K. The existing treatment options for bile duct cancer (cholangiocarcinoma) are mainly dominated by generics and off-label drugs, and provide only symptomatic relief. 

Request to Get the Sample Pages at:

The global bile duct cancer therapeutics market has been classified on the basis of disease indication, treatment type and geography. Based on disease indication, the global bile duct cancer therapeutics market has been segmented into perihilar (hilar) bile duct cancers, distal bile duct cancers, and intrahepatic bile duct cancers. Based on treatment type, the global bile duct cancer therapeutics market has been segmented into chemotherapy, chemoradiation and stent insertion. Based on region, the global market has been segmented into Latin America, North America, Asia-Pacific, Middle East & Africa, and Europe.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=bile-duct-cancer-therapeutics-market

Geographically, North America has been the largest market for bile duct cancer therapeutics. The growth of the regional market can be attributed to adequate reimbursement policies, greater awareness toward health care and advanced healthcare facilities. The Asia-Pacific and European markets for bile duct cancer therapeutics are projected to record strong CAGRs, over the forecast period.

Some of the key players in the global bile duct cancer therapeutics market include, Bayer, AG, Delcath Systems Inc., Senhwa Biosciences, Inc., PCI Biotech, Inc., ASLAN Pharmaceuticals, Inc., RedHill Biopharma Ltd. and Halozyme Therapeutics, Inc. among several others.

Read More

Benign Prostatic Hyperplasia Therapeutics Market Epidemiology Analysis, Therapy, Growth and Demand Forecast to 2023

The global benign prostatic hyperplasia therapeutics market is expected to witness significant growth, as increased number of effective treatments are available for cancer. Increasing awareness regarding various cancer treatment drugs, technological advancements, and growing demand for safe and effective medications are acting as the major growth drivers for the benign prostatic hyperplasia therapeutics market. Globally, regulatory bodies are adding to the growth of the market with provision of funding, grants and designations. Thus, these regulatory bodies are amplifying the drug development process. 

Benign prostatic hyperplasia is also known as benign prostatic obstruction or benign prostatic hypertrophy, is a disease state in men, caused by prostate gland enlargement. Prostate develops in dual phase in entire life – the first phase occurs in initial phase of puberty, followed by the second phase that usually begins at the age of twenty-four and remains for most of a person’s life. Benign prostatic hyperplasia is a common problem in men aged above 50 years, and it occurs in the second phase of growth of prostate. However, the disease can also arise in men aged below 40 years, with the probabilities of its occurrence increasing with age.

Request to Get the Sample Pages at:

Aging population is the major factor on which the benign prostatic hyperplasia therapeutics market is mostly dependent. Asia-Pacific and European markets for benign prostatic hyperplasia therapeutics are likely to observe significant growth rates, during the forecast period, due to increase in aging population in these regions. The Latin American and North American markets for benign prostatic hyperplasia therapeutics are also projected to observe strong growth rates, during the forecast period.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=benign-prostatic-hyperplasia-therapeutics-market

Some of the key players operating in the global benign prostatic hyperplasia therapeutics market include Sandoz, Inc., Sanofi Aventis, Labopharm, Inc., Pfizer, Inc., and Teva Pharmaceuticals, Inc.

Read More

Acute Myeloid Leukemia (AML) Therapeutics Market by Therapeutics, Diagnostics, Patient, Drugs Policy and Regulatory Landscape

The global acute myeloid leukemia therapeutics market is expected to witness notable growth, in the coming year due to increase in the new innovative and targeted drug delivery system. Various factors such as rising awareness regarding cancer treatments, increasing demand for safe and successful medications, rising incidence of cancer and technological advancements have been driving the growth of the global acute myeloid leukemia therapeutics market. Apart from this, various regulatory bodies are supporting the growth of the global market with funding, designations and grants, thereby accelerating the drug development process.

According to National Cancer Institute, a part of the U.S. National Institutes of Health, acute myeloid leukemia is a type of cancer that affects the blood and bone marrow. Acute myeloid leukemia is characterized by overproduction of immature white blood cells, myeloblasts or leukemic blasts. These cells crowd the bone marrow, preventing it from making normal blood cells. They can also spill out into the blood stream and circulate around the body. Due to their immaturity, these cells are unable to prevent or fight infections.

Download Report Sample at:

The pipeline of acute myeloid leukemia contains Durvalumab, a Phase II drug candidate of MedImmune. It is a fully human monoclonal antibody, which helps to overcome the immunosuppressive effects of B7-H1 on T-cells. Takeda Pharmaceutical Company Limited is developing a Phase II drug candidate, Alisertib, for the treatment of acute myeloid leukemia. It is an orally active, small-molecule inhibitor of the aurora A kinase. The aurora family of protein kinases is involved in the regulation of cell growth and proliferation, particularly in chromosome segregation and cytokinesis.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=acute-myeloid-leukemia-therapeutics-market

The acute myeloid leukemia therapeutics market was the largest market in the U.S. region of North America in year 2016, and it is expected to remain the largest during the forecast period due to large number of research and development activities.

Some of the key players operating in the acute myeloid leukemia therapeutics market include Celgene Corporation, Eisai Co. Ltd., Bristol-Myers Squibb, Novartis AG, F. Hoffman La Roche AG, Genmab A/S, GlaxoSmithKline plc, and Takeda Pharmaceutical Company Limited.

About P&S Intelligence

P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:

P&S Intelligence

Toll-free: +1-888-778-7886 (USA/Canada)           

International: +1-347-960-6455

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Read More

Acute Lymphoblastic Leukemia (ALL) Therapeutics Market Share Assessments for the Regional and Country Level Segments

The global acute lymphoblastic leukemia therapeutics market is expected to witness considerable growth in the coming year since new drug formulations are proving to be the most effective treatment for cancer. An increasing awareness regarding cancer treatment, various technological advancements, high demand for safe and effective medications and high prevalence of cancer, are driving the growth of the global acute lymphoblastic leukemia therapeutics market. The regulatory bodies are also supporting the growth of the global market by providing funding, designations and grants to speed up the drug development process. 

The pipeline of acute lymphoblastic leukemia contains GRASPA (Erythrocytes Encapsulating L-asparaginase), a Phase I drug candidate of ERYtech Pharma, Inc. GRASPA is an encapsulated L-asparaginase product, using the company’s proprietary ERYCAPS platform technology for the treatment of acute lymphoblastic leukemia in adults and children. GRASPA causes systemic degradation of asparagine and inhibits the growth and survival of cancer cells.

Download Report Sample Copy at:   

Certain chemotherapy medications such as Doxorubicin, Bleomycin, Vinblastine, Dacarbazine, Chlorambucil, Procarbazine Prednisolone, Mustine, Vincristine, Etoposide, Cyclophosphamide, Gemcitabine, Cisplatin and Cytarabine have been well established as a conventional method. Immunotherapy, combination therapy, monoclonal antibodies and steroids are showing good results for the treatment of acute lymphoblastic leukemia.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=acute-lymphoblastic-leukemia-therapeutics-market

Geographically, North America is expected to be the largest market for acute lymphoblastic leukemia, owing to a large number of research and development activities, high healthcare expenditure, and increasing prevalence of cancer. According to National Cancer Institute, estimated new cases of acute lymphoblastic leukemia were 6,590 and estimated deaths were 1,430 in 2016, in the U.S. The U.S. contributed the largest revenue to the North American market in 2016, and it is expected to remain the largest market, globally, during the forecast period.

Some of the key players operating in the global acute lymphoblastic leukemia treatment market are Spectrum Pharmaceuticals, Inc., Sigma-Tau Pharmaceuticals, Inc., ERYtech Pharma, Pfizer, Inc., Amgen, and Takeda Pharmaceutical Company Limited.

Contact:

P&S Intelligence

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +18887787886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Read More

Active Pharmaceutical Ingredients Market Opportunity Assessment Study

The global active pharmaceutical ingredient market is growing significantly due to patent expiry of biologic drugs in the industry. Patent expiry of blockbuster drugs has boosted the demand for low cost substitutes, which further increases the demand for active pharmaceutical ingredients in the industry. Moreover, increasing investment into biosimilars is expected to support the growth of the market in the coming years.

  

Massive unexplored market in active pharmaceutical ingredient industry of developing economies are creating ample opportunities for the active pharmaceutical ingredient market to grow at a considerable rate in the coming years. Active pharmaceutical ingredients are the primary components of manufacturing effective and safe essential drugs. The advanced research and development facilities of the companies are supporting to address the demand of the active pharmaceutical ingredient industry.

Download Free Sample of This Research Report: 

Geographically, North America will be leading the global active pharmaceutical ingredient market in the coming years due to increasing research and development programs in the field of drugs and medical science. Asia-Pacific is the fastest growing region in the global active pharmaceutical ingredient market. The major reasons for the fastest growth of the market in the region are increasing healthcare expenditure, large pool of patients, and presence of large pool of generic medicine producers in the region. Moreover, the active pharmaceutical ingredient market is growing due to increasing awareness of lifestyle associated diseses in the emerging countries, such as India and China, of Asia-Pacific region.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=active-pharmaceutical-ingredients-market

Some of the companies operating in the active pharmaceutical ingredient market are Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories, Actavis Plc, Hospira Inc., Boehringer Ingelheim Group, Lonza Group, Cambrex Corporation, Novartis International AG, BASF SE, Pfizer, Inc., Mylan, Inc., Watson Pharmaceutical Inc., and WuXi Apptec.

Read More